Condition

Dumping Syndrome

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 3 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting0

Common interventions6

Lead sponsors shown3

Clinical trials

3 shown

Comparing Dumping Symptoms and Quality of Life 6 Months After Sleeve Gastrectomy With or Without Transit Bipartition in Adults With ObesityNCT07263269 · 2024-04-06

ACTIVE_NOT_RECRUITING

Impact of an Educational Personalized Clinical Support Device Preventive and a Referent Nurse in Surgery for ObesityNCT02891330 · 2017-03-02

COMPLETED

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored StudiesNCT01794793 · 2013-06-10

COMPLETED

Common interventions

CabergolineDRUG1 Dietary and nutritional recommendations conducted by a nurseBEHAVIORAL1 PasireotideDRUG1 Pasireotide LARDRUG1 Sleeve GastrectomyPROCEDURE1 Sleeve Gastrectomy with Transit BipartitionPROCEDURE1

Leading sponsors

Mina Kamal Gergis Erian 1 RECORDATI GROUP 1 University Hospital, Lille 1

Trial status mix

COMPLETED2

ACTIVE_NOT_RECRUITING1

Phase mix

NA2

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.